US Patent

US11285134 — Presbyopia treatments

Method of Use · Assigned to Allergan Inc · Expires 2039-04-24 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating ocular conditions, including presbyopia, using pilocarpine formulations.

USPTO Abstract

Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.

Drugs covered by this patent

pilocarpine-hydrochloride (PILOCARPINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3561`	—	pilocarpine-hydrochloride

Patent Metadata

Patent number: US11285134
Jurisdiction: US
Classification: Method of Use
Expires: 2039-04-24
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.